EUVIMEDEUVIMED entdecken
Crossref

177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma

Yadong Wang, Long Qiu, Tianzhen Ye, Fuyuan Tan, Jie Lyu, Feize Li, Zhizhong Sun, Yuanyou Yang, Jinsong Zhang, Ning Liu iD, Jiali Liao

ChemBioChem · 2025

DOI: 10.1002/cbic.202400579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Yadong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610000, China. Hauptthemen laut MEDLINE: Indoles, Polymers, Glioma, Lutetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Joint Innovation Fund of Sichuan University and Nuclear Power Institute of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radionuclide therapy is expected to be a powerful tool for glioma treatment. Here, we introduced a novel nuclear nanomedicine based on polydopamine (PDA), incorporating fibroblast activation protein inhibitor (FAPI) and macrocyclic chelator (DOTA) for specific cancer targeting and 177 Lu labeling. The synthesized nanoradiopharmaceutical, 177 Lu‐DOTA‐PEG‐PDA‐FAPI, exhibits good stability in serum, saline and PBS over 5 days. 177 Lu‐DOTA‐PEG‐PDA‐FAPI shows efficient specific uptake and internalization when incubated with U87MG cells. In vivo distribution visualized prominent accumulation and long retention ability of 177 Lu‐DOTA‐PEG‐PDA‐FAPI at tumor sites after local administration. Moreover, 177 Lu‐DOTA‐PEG‐PDA‐FAPI has satisfactory antitumor ability without apparent toxic and side effects observed from therapy assay and H&E staining. This study highlights the feasibility of using PDA as a nanocarrier for glioma endoradiotherapy by targeting fibroblast activation protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesPolymersGliomaLutetiumRadioisotopesRadiopharmaceuticalsMembrane ProteinsAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorTissue DistributionEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

177LuFibroblast activation protein inhibitorGliomaPolydopamineTherapy

Substanzen

IndolesPolymersLutetiumRadioisotopesRadiopharmaceuticalsMembrane ProteinsAntineoplastic AgentsEndopeptidasesFibroblast Activation Protein Alphapolydopamine

Autor:innen und Institutionen

  • Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610000, China.
  • Sichuan Engineering Research Center for Radioactive Isotope, National Engineering Research Center for Isotopes and Pharmaceuticals, Nuclear Power Institute of China, Chengdu, 610000, China.

ORCID-Profile: Ning Liu

Förderung

  • National Natural Science Foundation of China
  • Joint Innovation Fund of Sichuan University and Nuclear Power Institute of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Wang, Y., Qiu, L., Ye, T., Tan, F., Lyu, J., Li, F., Sun, Z., Yang, Y., Zhang, J., Liu, N., & Liao, J. (2025). 177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma. ChemBioChem. https://doi.org/10.1002/cbic.202400579

Vancouver

Wang Y, Qiu L, Ye T, Tan F, Lyu J, Li F, et al. 177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma. ChemBioChem. 2025. doi:10.1002/cbic.202400579

BibTeX
@article{Wang2025,
  author = {Wang, Yadong and Qiu, Long and Ye, Tianzhen and Tan, Fuyuan and Lyu, Jie and Li, Feize and Sun, Zhizhong and Yang, Yuanyou and Zhang, Jinsong and Liu, Ning and Liao, Jiali},
  title = {177 Lu Radiolabeled Polydopamine Decorated with Fibroblast Activation Protein Inhibitor for Locoregional Treatment of Glioma},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202400579}
}
Kostenlos starten →